Table 1.
Characteristics of fasted participants after a 4-week administration of bezafibrate or control
| Bezafibrate | Control | p | |
|---|---|---|---|
| Body mass index (kg/m2) |
28.8 ± 1.2 |
28.6 ± 1.1 |
0.24 |
| Systolic blood pressure (mmHg) |
127 ± 4 |
125 ± 4 |
0.34 |
| Diastolic blood pressure (mmHg) |
78 ± 3 |
80 ± 2 |
0.98 |
| Heart rate (beats/min) |
64 ± 2 |
65 ± 1 |
0.20 |
|
Laboratory data |
|
|
|
| Total-C (mg/dl) |
217 ± 9 |
197 ± 8 |
0.02 |
| LDL-C (mg/dl) |
129 ± 6 |
135 ± 9 |
0.57 |
| HDL-C (mg/dl) |
46 ± 3 |
43 ± 3 |
0.22 |
| TG (mg/dl) |
135 ± 24 |
203 ± 35 |
<0.01 |
| RLP-C (mg/dl) |
5.7 ± 0.7 |
7.9 ± 1.3 |
0.02 |
| ApoB-48 (μg/ml) |
3.5 ± 0.7 |
6.0 ± 1.5 |
0.02 |
| Glucose (mg/dl) |
97 ± 3 |
101 ± 5 |
0.15 |
| Insulin (μU/ml) |
12.7 ± 4.8 |
8.5 ± 1.4 |
0.43 |
| HOMA-IR |
2.9 ± 0.2 |
2.1 ± 0.2 |
0.48 |
| Hemoglobin A1c (%) |
5.2 ± 0.3 |
5.3 ± 0.3 |
0.17 |
| Pentraxin 3 (ng/ml) |
1.5 ± 0.2 |
1.5 ± 0.2 |
0.64 |
|
Endothelial function |
|
|
|
| Brachial artery diameter (mm) |
4.3 ± 0.2 |
4.3 ± 0.2 |
0.70 |
| % FMD | 6.9 ± 0.7 | 5.9 ± 0.7 | 0.04 |
Data are mean ± SE. Total-C, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TGs, triglycerides; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; HOMA-IR, homeostasis model assessment of insulin resistance; FMD, flow-mediated dilation.